These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36441070)

  • 21. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach.
    Liu WK; Lam JM; Butters T; Grant M; Jackson-Spence F; Bex A; Powles T; Szabados B
    World J Urol; 2020 Dec; 38(12):3199-3205. PubMed ID: 32128610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Dahm P; Ergun O; Uhlig A; Bellut L; Risk MC; Lyon JA; Kunath F
    Cochrane Database Syst Rev; 2024 Jun; 6(6):CD013773. PubMed ID: 38847285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma.
    Hara T; Furukawa J; Shiraishi Y; Okamura Y; Bando Y; Terakawa T; Harada K; Nakano Y; Fujisawa M
    Int J Urol; 2023 Sep; 30(9):746-752. PubMed ID: 37130778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Shifting role of cytoreductive nephrectomy according to type of systemic therapy: A nationwide cohort study.
    Choi SY; Ha MS; Lee JW; Kim JH; Kim JH; Chi BH; Kim JW; Chang IH; Kim TH; Myung SC
    Asian J Surg; 2023 Jan; 46(1):328-336. PubMed ID: 35450758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
    Fiala O; Buti S; Bamias A; Massari F; Pichler R; Maruzzo M; Grande E; De Giorgi U; Molina-Cerrillo J; Seront E; Calabrò F; Myint ZW; Facchini G; Kopp RM; Berardi R; Kucharz J; Vitale MG; Pinto A; Formisano L; Büttner T; Messina C; Monteiro FSM; Battelli N; Kanesvaran R; Büchler T; Kopecký J; Santini D; Giudice GC; Porta C; Santoni M
    Target Oncol; 2024 Jul; 19(4):587-599. PubMed ID: 38704759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis.
    Ghatalia P; Handorf EA; Geynisman DM; Deng M; Zibelman MR; Abbosh P; Anari F; Greenberg RE; Viterbo R; Chen D; Smaldone MC; Kutikov A; Uzzo RG
    J Urol; 2022 Jul; 208(1):71-79. PubMed ID: 35212574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Britton CJ; Andrews JR; Wallis CJD; Sharma V; Leibovich BC; Thompson RH; Boorjian SA; Bhindi B; Costello BA
    Urol Oncol; 2023 Mar; 41(3):125-136. PubMed ID: 38832909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
    Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
    Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?
    Méjean A; Ravaud A; Thezenas S; Chevreau C; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Oudard S; Laguerre B; Gross-Goupil M; Bernhard JC; Colas S; Albiges L; Lebret T; Treluyer JM; Timsit MO; Escudier B
    Eur Urol; 2021 Oct; 80(4):417-424. PubMed ID: 34187771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.
    Napolitano L; Manfredi C; Cirillo L; Fusco GM; Passaro F; Abate M; La Rocca R; Mastrangelo F; Spirito L; Pandolfo SD; Crocetto F; Arcaniolo D; Barone B
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?
    Dariane C; Timsit MO; Méjean A
    Bull Cancer; 2018 Dec; 105 Suppl 3():S229-S234. PubMed ID: 30595151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma.
    Andrews JR; Lohse CM; Boorjian SA; Leibovich BC; Thompson H; Costello BA; Bhindi B
    Urol Oncol; 2022 Apr; 40(4):166.e1-166.e8. PubMed ID: 35168879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
    Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database.
    Park CL; Moria FA; Ghosh S; Wood L; Bjarnason GA; Bhindi B; Heng DYC; Castonguay V; Pouliot F; Kollmannsberger CK; Bosse D; Basappa NS; Finelli A; Fallah-Rad N; Breau RH; Lalani AA; Tanguay S; Graham J; Saleh RR
    Curr Oncol; 2024 Aug; 31(8):4704-4712. PubMed ID: 39195334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting.
    Ljungberg B; Sundqvist P; Lindblad P; Kjellman A; Thorstenson A; Hellström M; Kröger Dahlin BI; Thomasson M; Harmenberg U; Lundstam S
    Scand J Urol; 2020 Dec; 54(6):487-492. PubMed ID: 32897123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
    Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
    Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
    Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
    Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of cytoreductive surgery in the era of immunotherapy.
    Isali I; Braun A; Bukavina L; Psutka SP
    Curr Opin Urol; 2022 Nov; 32(6):618-626. PubMed ID: 36081404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?
    Larcher A; Wallis CJD; Bex A; Blute ML; Ficarra V; Mejean A; Karam JA; Van Poppel H; Pal SK
    Eur Urol Oncol; 2019 Jul; 2(4):365-378. PubMed ID: 31109902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma.
    Mittal A; Al-Ezzi E; Li X; Moloney B; Wilson B; Spiliopoulou P; Sridhar S; Fallah-Rad N; Chung P; Hamilton RJ; O'malley M; Hansen AR
    Br J Cancer; 2023 May; 128(10):1888-1896. PubMed ID: 36859686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.